🔬 Latest pharma industry updates 👇

🤝 Jazz Pharmaceuticals will acquire Actio Biosciences, Inc. for up to $1.3B, adding a rare epilepsy drug and expanding its neuroscience pipeline.

✅ FDA granted accelerated approval to Bristol Myers Squibb’s Zenbexus combination in 2nd-line multiple myeloma, validating the company’s CELMoD platform.

🤝 Innate Pharmaa partnered with Sobi - Swedish Orphan Biovitrum AB (publ) to fund and run Phase 3 development of lacutamab in CTCL, receiving $75M upfront and up to $505M in milestones.

❌ Sionna Therapeutics’s cystic fibrosis drug failed to add meaningful benefit when combined with Vertex’s Trikafta.

🔄 PDS Biotechnology halted proprietary funding of its Phase 3 PDS0101 study to seek partners, shifting resources toward PDS0301 after encouraging colorectal cancer data.

💰 Vaderis Therapeutics AG raised $152M to advance a more selective AKT inhibitor for hereditary hemorrhagic telangiectasia, a rare vascular disorder with limited treatment options.

📈 Definium Therapeutics reported another positive late-stage result for its LSD-based DT120, this time in generalized anxiety disorder, reinforcing analysts’ view of potential multibillion-dollar commercial value.

⚠️ Eli Lilly and Company filed 6 lawsuits targeting black-market sellers of experimental obesity drug retatrutide, warning that unauthorized versions may be fake, impure or incorrectly dosed.

🫁 Taiho Oncology, Inc. and Cullinan Therapeutics’s zipalertinib combination succeeded early in Phase 3 first-line EGFR exon 20 lung cancer, showing a significant progression-free survival benefit and prompting study unblinding.

🧬 PTC Therapeutics, Inc. will acquire Sangamo Therapeutics, Inc.’s Fabry gene therapy for up to $211M, planning to complete its FDA filing and potentially launch the one-time treatment in 2027.

📈 Capricor Therapeutics, Inc. shares surged after FDA signaled openness to reviewing an amended deramiocel filing in Duchenne, with new follow-up data potentially supporting a narrower indication.

⚖️ Cytokinetics sued Bristol Myers Squibb over patents tied to hypertrophic cardiomyopathy treatment Myqorzo, seeking to protect its newly launched drug from potential litigation involving rival Camzyos.

💉 EMA accepted Pfizer and Valneva’s Lyme disease vaccine application, significantly de-risking the program despite mixed pivotal data and shifting attention toward approval prospects in Europe and the U.S.

🤝 Zealand Pharma sold most of its rusfertide royalty rights to Royalty Pharma for $100M, retaining a small upside if global annual sales exceed $1.5B.